Pharmaceutical composition for preventing or treating nail and skin tinea

WO2024185956A3PCT designated stage expired Publication Date: 2024-11-07CHANG BYEUNG MO
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/018987
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-03
Filing Date
2023-11-23
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current antifungal drugs for treating nail and skin ringworm face issues such as low solubility leading to crystal precipitation, reduced penetration due to high affinity for keratin, and the presence of harmful ingredients like cyclomethicone, N-methylpyrrolidone, and ethylenediamine tetraacetic acid salt, which are environmentally hazardous and carcinogenic.

Method used

A pharmaceutical composition incorporating an antifungal agent like efinaconazole, a crystal growth inhibitor (1,2-pentanediol and acetyltributyl citrate), and a keratin affinity inhibitor (cystamine dihydrochloric acid) to prevent crystal formation and enhance skin and nail penetration, while avoiding harmful substances.

Benefits of technology

The composition improves solubility, prevents crystal precipitation, increases drug penetration, and enhances antibacterial activity, offering effective prevention and treatment of ringworm while being environmentally friendly and safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023018987_07112024_PF_FP_ABST
    Figure KR2023018987_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed is a pharmaceutical composition for preventing or treating nail and skin tinea. The pharmaceutical composition for preventing or treating nail and skin tinea, according to one embodiment, may comprise: an antifungal agent; a crystal growth inhibitor; and a keratin affinity inhibitor. The composition according to one embodiment is a pharmaceutical composition which, as an external preparation containing the antifungal agent, inhibits crystal growth during storage, prevents crystal precipitation after application, inhibits keratin affinity, and thereby has improved skin and nail permeability and antibacterial power. The composition may comprise the antifungal agent as an active ingredient, and the crystal growth inhibitor, the keratin affinity inhibitor, a chelating agent, and an additive (e.g., a vehicle, an antioxidant, or a pH adjuster) as auxiliary ingredients.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis

[0001] The present disclosure relates to a pharmaceutical composition for the prevention or treatment of tinea capitis and skin dermatitis.

[0002] Tinea is a general term for superficial fungal infections caused by dermatophytes. Dermatophytes are keratinophilic fungi that possess keratinase, which can dissolve keratin, and parasitize the keratin of the stratum corneum of the epidermis, hair, fingernails, and toenails.

[0003] Typically, tinea is classified into tinea captis, tinea coporis, tinea cruris, tinea barbae, tinea faciel, tinea manus, tinea pedis, and tinea unguium depending on the site of occurrence [Byung Ho Oh, Kyu Joong Ahan. "Drug Therapy of Dermatophytosis" J Korean Med. Assoc. 2009, 52(11):1109-1114].

[0004] The causative agent of tinea versicolor may vary depending on the site of occurrence and the patient's age, but common causative agents include Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyt floccosum, Microsporum canis, Candida albicans as a yeast, and Aspergillus niger as a fungus.

[0005] Among the various causative agents of tinea, Trichophyton leucorrhizae accounts for 60% and Trichophyton mentagrophytes accounts for 20%. In particular, tinea onychomycosis occurs frequently in people over 40 years of age, and Trichophyton leucorrhizae accounts for 91.0% and Trichophyton mentagrophytes accounts for 7.7% of the causative agents of tinea onychomycosis [Uwe Wollina, Holger Haenssle, Dtsch Arztebl Int. 2016;113(29-30):509-518].

[0006] Depending on the route and location of fungal invasion into the nail, onychomycosis can be classified into ① distal and lateral subungual onychomycosis (DLSO), ② proxmimal subungual onychomycosis (PSO), ③ white superficial onychomycosis (WSO), ④ endonyx onychomycosis (EO), and ⑤ total dystrophic onychomycosis (TDO).

[0007] Meanwhile, antifungal agents are largely classified into polyenes, azoles, allylamines, benzylamines, morpholines, hydroxypyridones, and oxaboroles. Among these, luliconazole (1% cream / 5% solution), efinaconazole (10% solution), terbinafine (1% cream / spray), amorolfine (5% nail lacquer), ciclopirox (8% nail lacquer), and tavaborole (5% solution) are widely sold as treatments for onychomycosis.

[0008] However, most antifungal agents have low solubility, which can lead to crystal precipitation due to temperature changes during storage, or to crystal precipitation easily occurring when the drug is applied to the affected area and dried. This crystal precipitation pattern can be explained by the Ostwald ripening theory, which states that particles with high equilibrium concentration and small particle size in a solution dissolve into particles with low equilibrium concentration and large particle size, forming even larger particles.

[0009] In addition, existing antifungal agents have encountered technical limitations in preventing and treating tinea versicolor, as their drug penetration effect is significantly reduced due to their high affinity for keratin in the skin and nails.

[0010] Meanwhile, currently widely sold antifungal products include Jubulia (Efinaconazole 10%), which contains cyclomethicone and ethylenediamine tetraacetic acid salt, Luconac (Luliconazole 5%), which contains N-methylpyrrolidone, and Kerydin (Tavabole 5%), which contains ethylenediamine tetraacetic acid salt.

[0011] However, due to its environmental hazards, cyclomethicone's use is restricted in each country, and methylpyrrolidone is classified as a carcinogen, mutagen, or reproductive toxicant, and its use is strictly regulated as a hazardous substance. Furthermore, ethylenediaminetetraacetic acid, long used as a chelating agent, is poorly biodegradable and can deposit heavy metals in soil and water, potentially leading to their influx into the food chain. Therefore, its use is not desirable from an environmental perspective.

[0012] Therefore, there is a need for the development of a new technology that can not only resolve the problems caused by harmful ingredients contained in currently commercially available products, but also improve the solubility of antifungal agents by inhibiting crystal growth, and significantly improve the skin and nail penetration ability and antibacterial effect by reducing the keratin affinity of antifungal agents.

[0013] [Prior Art Literature]

[0014] [Non-patent literature]

[0015] (Non-patent Document 1) 1. Byung Ho Oh, Kyu Joong Ahan. “Drug Therapy of Dermatophytosis” J Korean Med. Assoc. 2009, 52(11):1109-1114.

[0016] (Non-patent literature 2)2. Uwe Wollina, Holger Haenssle, Dtsch Arztebl Int. 2016; 113(29-30):509-518.

[0017] The technical idea of ​​the present disclosure is to solve the above-described problems, and the purpose is to provide a technology that can improve storage stability and enhance the therapeutic effect of the drug by preventing the antifungal agent from precipitating into crystals.

[0018] In addition, the technical idea of ​​the present disclosure has another purpose of providing a technology for increasing the penetration ability of the skin and nail by reducing the keratin affinity of an antifungal agent.

[0019] In addition, another purpose of the technical idea of ​​the present disclosure is to provide a technology that can fundamentally solve problems arising from the use of cyclomethicone, methylpyrrolidone, and ethylenediamine tetraacetic acid salt.

[0020] The problems to be solved by the present invention are not limited to the problems described above, and other technical problems not mentioned will be clearly understood by those skilled in the art to which the present invention pertains from the contents described below.

[0021] In order to achieve this purpose, as one embodiment of the present invention, a pharmaceutical composition for preventing or treating tinea pedis and skin ringworm comprises an antifungal agent; a crystal growth inhibitor; a keratin affinity inhibitor; and an additive; wherein the antifungal agent comprises efinaconazole, and the content of the antifungal agent is 10 wt% based on the total weight of the composition, and the crystal growth inhibitor comprises 1,2-pentanediol in a weight ratio of 1:2; And acetyltributyl citrate; and the content of the crystal growth inhibitor is 0.1 to 30 wt% based on the total weight of the composition, the keratin affinity inhibitor includes cystamine dihydrochloride or octenidine dihydrochloride, the content of the keratin affinity inhibitor is 0.01 to 10 wt% based on the total weight of the composition, and the causative agent of tinea includes at least one selected from Trichophyton leucorrhiza, Trichophyton mentagrophytes, and Candida albicans.

[0022] Meanwhile, the pharmaceutical composition for preventing or treating tinea versicolor may further include a chelating agent.

[0023] And, the content of the chelating agent can be applied at 0.0001 to 5 wt% with respect to the total weight of the composition.

[0024] Additionally, the chelating agent may include trisodium ethylenediamine disuccinate.

[0025] Additionally, the additive may include at least one selected from a vehicle, an antioxidant, and a pH adjuster.

[0026] And, the pharmaceutical composition for preventing or treating tinea can be prepared in at least one formulation selected from liquid, aerosol, stick and semi-solid formulations.

[0027] Additionally, the semi-solid preparation may include at least one of a gel, a lotion, a cream, and an ointment.

[0028] Additionally, the pH of the pharmaceutical composition for preventing or treating vitiligo can be applied at 2 to 10.

[0029] And, the density of the pharmaceutical composition for preventing or treating vitiligo can be applied at 0.5 to 2 g / cm3.

[0030] In addition, a pharmaceutical composition for preventing or treating vitiligo can be applied with a moisture content of 0.1 to 90 wt% as measured by the Karl Fischer method.

[0031] And, the surface tension of the pharmaceutical composition for preventing or treating vitiligo may be 1 to 76 dyn / cm.

[0032] The solutions to the above-described problems are merely exemplary and should not be construed as limiting the scope of the present invention. In addition to the exemplary embodiments described above, additional embodiments may exist, as described in the drawings and detailed description of the invention.

[0033] As described above, according to various embodiments of the present invention, by inhibiting crystal growth of the poorly soluble antibacterial agents luliconazole, efinaconazole, and tavaborole as active ingredients, the solubility of the drug is improved, so that the phenomenon of crystal precipitation does not occur even when the temperature changes during long-term storage, and when the drug is applied to the affected area of ​​the skin or nail, the formation of fine precipitates in the affected area after the volatile solvent evaporates is prevented, thereby significantly improving the permeability of the drug.

[0034] In addition, according to various embodiments of the present invention, the crystal growth of the drug is suppressed, so that no precipitate is formed, and the antibacterial activity is excellent.

[0035] In addition, according to various embodiments of the present invention, when applying the drug to the affected area of ​​the skin and nail, the keratin affinity of the antibacterial agent, which is an active ingredient, is suppressed, thereby further increasing the drug permeability, thereby having an excellent effect in preventing and treating tinea skinae and tinea onychomycosis.

[0036] In addition, according to various embodiments of the present invention, the effect of preventing crystal precipitation after drug application is excellent, so that medication compliance is high, and the drug permeability and antibacterial power in the skin and nails are very excellent.

[0037] In addition, it does not contain cyclomethicone and N-methylpyrrolidone, which are regulated substances contained in products currently on the market, and ethylenediamine tetraacetic acid salt, which has poor biodegradability, so it is less harmful and more environmentally friendly than products containing these ingredients, and can be widely used as a pharmaceutical composition for external application for the prevention or treatment of tinea capitis and tinea onychomycosis.

[0038] The effects according to various embodiments of the present invention are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description of the claims.

[0039] Figure 1 is a graph showing the cumulative permeation concentration results of luriconazole for 10 days according to Control Example 1, Comparative Example 1, and Manufacturing Examples 1 to 5.

[0040] Figure 2 is a graph showing the cumulative permeation concentration results of efinaconazole for 10 days according to Control Example 2, Comparative Example 2, and Manufacturing Examples 6 to 10.

[0041] Figure 3 is a graph showing the cumulative permeation concentration results of tababolol for 10 days according to Control Example 3, Comparative Example 3, and Manufacturing Examples 11 to 15.

[0042] A preferred embodiment of the present invention will be described in more detail with reference to the attached drawings, but technical parts already known will be omitted or compressed for the sake of brevity.

[0043] It should be noted that references in this specification to “one” or “an” embodiment of the invention are not necessarily to the same embodiment, but rather mean at least one.

[0044] In the examples below, singular expressions include plural expressions unless the context clearly indicates a different meaning.

[0045] In the examples below, terms such as “include” or “have” mean that a feature or component described in the specification is present, and do not preclude the possibility that one or more other features or components may be added.

[0046] As used herein, the term “prevention” means any act of inhibiting or delaying the occurrence, spread or recurrence of a disease by administering a pharmaceutical composition according to various embodiments of the present invention.

[0047] As used herein, the term “treatment” means any action by which the symptoms of a disease are improved or beneficially changed by administration of a pharmaceutical composition according to various embodiments of the present invention.

[0048] As used herein, the term “administration” means providing an active ingredient to a subject by any suitable method.

[0049] The term "subject" as used herein includes, but is not limited to, mammals including humans, guinea pigs, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats or rabbits, and preferably may be humans.

[0050] In this specification, the term “topical agent” means a medicine administered by applying, spraying, or attaching to the skin.

[0051] As used herein, the term "pharmaceutically acceptable" means physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset, dizziness, or similar reactions when administered to humans.

[0052] As used herein, the term "salt" means an acid addition salt formed by a pharmaceutically acceptable free acid. Accordingly, a pharmaceutically acceptable salt means a salt commonly used in the pharmaceutical industry, for example, an inorganic ionic salt prepared with calcium, potassium, sodium or magnesium, etc.; an inorganic acid salt prepared with hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, iodic acid, perchloric acid or sulfuric acid, etc.; an organic acid salt prepared with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid or vanillic acid, etc. Sulfonate salts made with methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, salicylic acid, p-toluenesulfonic acid or naphthalenesulfonic acid; amino acid salts made with glycine, arginine or lysine; or amine salts made with trimethylamine, triethylamine, ammonia, pyridine or picoline; etc.; However, the types of salts meant in this specification are not limited by these listed salts.

[0053] In this specification, the term "density" refers to a value indicating mass per unit volume, generally expressed in units of g / cm3. The density described in this specification It can be measured by a surface tension meter (Easy Dyne surface tension meter model K20) sold by the company.

[0054] As used herein, the term "moisture content" refers to the moisture content contained in a pharmaceutical composition, expressed as a percentage. The moisture content described herein is measured by the Karl Fischer titration method, and a Metrohm 901 KF Titrando moisture meter can be used for the measurement.

[0055] As used herein, the term "surface tension", generally expressed in units of dyn / cm, means the force required to increase the unit area of ​​a liquid surface or the unit area of ​​an interface between two liquids or between a liquid and a gas. The surface tension described herein is De Nuy ring surface tension method (Du) using a surface tensiometer (Easy Dyne surface tensiometer model K20) sold by It is measured by the Ring Method.

[0056] A pharmaceutical composition for preventing or treating tinea according to one embodiment may include an antifungal agent as an active ingredient and may further include auxiliary ingredients (e.g., crystal growth inhibitors, keratin affinity inhibitors, chelating agents, additives, etc.). In one specific example, the pharmaceutical composition for preventing or treating tinea cutis and tinea onychomycosis may be implemented as a pharmaceutical composition for topical application containing an antifungal agent.

[0057] A pharmaceutical composition for the prevention or treatment of tinea according to one embodiment may include an antifungal agent, a crystal growth inhibitor, and a keratin affinity inhibitor. In one embodiment, the content of the antifungal agent may be 0.1 to 20 wt% based on the total weight of the composition.

[0058] As a specific example, the content of the antifungal agent is 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt%, 8 wt%, 8.5 wt%, 9 wt%, 9.5 wt%, 10 wt%, 10.5 wt%, 11 wt%, 11.5 wt%, 12 wt%, 12.5 wt%, 13 wt%, 13.5 wt%, 14 wt%, It can be prepared as 14.5 wt%, 15 wt%, 15.5 wt%, 16 wt%, 16.5 wt%, 17 wt%, 17.5 wt%, 18 wt%, 18.5 wt%, 19 wt%, 19.5 wt% or 20 wt%. In addition, the content of the antifungal agent can be in a range of one or more of the above values ​​and one or less of the above values.

[0059] For example, the content range of the antifungal agent can be set to be 0.1 wt% to 18 wt%, 0.5 wt% to 17 wt%, 1 wt% to 16 wt%, 2 wt% to 15 wt%, 3 wt% to 14 wt%, 4 wt% to 13 wt%, 5 wt% to 20 wt%, 8 wt% to 20 wt%, 10 wt% to 16 wt%, 1 wt% to 10 wt%, 5 wt% to 15 wt%, or 0.1 wt% to 20 wt%.

[0060] In addition, the content of the antifungal agent may be applied as one or more of the above values, or may be applied as one or less of the above values. For example, the content of the antifungal agent may be applied as 0.1 wt% or more, 0.5 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, 5 wt% or more, 6 wt% or more, 7 wt% or more, or 8 wt% or less, 20 wt% or less, 19 wt% or less, 18 wt% or less, 17 wt% or less, 16 wt% or less, 15 wt% or less, 14 wt% or less, 13 wt% or less, 12 wt% or less, 11 wt% or less, or 10 wt% or less.

[0061] In one embodiment, the antifungal agent may be administered in an amount effective for the prevention or treatment of tinea cutis and tinea unguium. The level of the effective amount for the prevention or treatment of tinea cutis and tinea unguium may be determined based on factors including the type and severity of the patient's disease, the activity and sensitivity of the drug, the time of administration, the route of administration, the rate of excretion, the duration of treatment, concomitant medications, and other factors well known in the medical field. Taking all of the aforementioned factors into account, it is important to administer an amount that achieves the maximum effect with the minimum amount without adverse effects, and this can be readily determined by those skilled in the art.

[0062] In one embodiment, the antifungal agent is a chemical substance that exhibits bactericidal activity against Trichophyton rubrum, Trichophyton mentagrophytes, Candida albicans, etc., and the type of antifungal agent is not limited to a specific type as long as it exhibits antibacterial activity against the aforementioned fungi.

[0063] In one embodiment, the antifungal agent may include at least one selected from the group consisting of azole and oxaborole antibacterial agents, such as luriconazole, luriconazole salts, efinaconazole, efinaconazole salts, tavaborole, and tavaborole salts.

[0064] In one specific example, the structural formula of luriconazole can be represented by the following chemical formula 1.

[0065] [Chemical Formula 1]

[0066]

[0067] In addition, in one specific example, the luriconazole salt may be applied as at least one selected from the group consisting of an inorganic ionic salt, an inorganic acid salt, an organic acid salt, a sulfonate salt, an amino acid salt, and an amine salt as a pharmaceutically acceptable salt of luriconazole.

[0068] In one specific example, the structural formula of efinaconazole can be represented by the following chemical formula 2.

[0069] [Chemical Formula 2]

[0070]

[0071] In addition, in one specific example, the efinaconazole salt may be applied as at least one selected from the group consisting of an inorganic ionic salt, an inorganic acid salt, an organic acid salt, a sulfonate salt, an amino acid salt, and an amine salt as a pharmaceutically acceptable salt of efinaconazole.

[0072] In one specific example, the structural formula of tababorole can be represented by the following chemical formula 3.

[0073] [Chemical Formula 3]

[0074]

[0075] In addition, in one specific example, the tababorole salt may be applied as at least one selected from the group consisting of an inorganic ionic salt, an inorganic acid salt, an organic acid salt, a sulfonate salt, an amino acid salt, and an amine salt as a pharmaceutically acceptable salt of tababorole.

[0076] In one embodiment, a crystal growth inhibitor may inhibit the crystallization of a specific ingredient included in a pharmaceutical composition. For example, a crystal growth inhibitor may prevent an antifungal agent included in the composition from crystallizing.

[0077] In one embodiment, the content of the crystal growth inhibitor may be 0.1 to 70 wt% based on the total weight of the composition. As a specific example, the content of the crystal growth inhibitor is 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt%, 8 wt%, 8.5 wt%, 9 wt%, 9.5 wt%, 10 wt%, 10.5 wt%, 11 wt%, 11.5 wt%, 12 wt%, 12.5 wt%, 13 wt%, 13.5 wt%, 14 wt%, 14.5 wt%, 15 wt%, 15.5 wt%, 16 wt%, 16.5 wt%, 17 wt%, 17.5 wt%, 18 wt%, 18.5 wt%, 19 wt%, 19.5 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 65 wt% or 70 wt%. In addition, the content of the crystal growth inhibitor can be in a range of one or more of the above values ​​and one or less of the above values.

[0078] For example, the content range of the crystal growth inhibitor can be set to be 0.1 wt% to 18 wt%, 0.5 wt% to 17 wt%, 1 wt% to 16 wt%, 2 wt% to 15 wt%, 3 wt% to 14 wt%, 4 wt% to 13 wt%, 5 wt% to 20 wt%, 8 wt% to 20 wt%, 10 wt% to 16 wt%, 1 wt% to 10 wt%, 5 wt% to 15 wt%, 0.1 wt% to 20 wt%, 10 wt% to 15 wt%, 10 wt% to 30 wt%, 10 wt% to 40 wt%, 20 wt% to 50 wt%, 30 wt% to 60 wt%, 40 wt% to 70 wt% or 0.1 wt% to 70 wt%.

[0079] And, the content of the crystal growth inhibitor may be applied as one or more of the above values, or may be applied as one or less of the above values. For example, the content of the crystal growth inhibitor may be applied as 0.1 wt% or more, 0.5 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, 5 wt% or more, 6 wt% or more, 7 wt% or more, 8 wt% or more, 9 wt% or more, 10 wt% or more, or 15 wt% or less, or 70 wt% or less, 60 wt% or less, 50 wt% or less, 40 wt% or less, 30 wt% or less, 20 wt% or less, or 10 wt% or less.

[0080] In one embodiment, the crystal growth inhibitor may include 1,2-pentanediol and an ester compound. Further, in one embodiment, the ester compound may be at least one selected from the group consisting of acetyltributyl citrate, acetyltriethyl citrate, triethyl citrate, and diethyl carbonate.

[0081] In one embodiment, the weight ratio of 1,2-pentanediol and the ester compound may be applied as 1:2. If the weight ratio between 1,2-pentanediol and the ester compound exceeds 1:2, crystals may precipitate or sediment may occur during storage of the composition, which may negatively affect the penetration ability and antibacterial activity of the composition.

[0082] In one embodiment, the keratin affinity inhibitor can inhibit the adsorption of the antifungal agent to keratin of the skin or nail. In one embodiment, the content of the keratin affinity inhibitor can be 0.01 to 30 wt% based on the total weight of the composition.

[0083] As a specific example, the content of the keratin affinity inhibitor is 0.01 wt%, 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt%, 8 wt%, 8.5 wt%, 9 wt%, 9.5 wt%, 10 wt%, 10.5 wt%, 11 wt%, 11.5 wt%, 12 wt%, 12.5 wt%, The amount of the keratin affinity inhibitor may be 13 wt%, 13.5 wt%, 14 wt%, 14.5 wt%, 15 wt%, 15.5 wt%, 16 wt%, 16.5 wt%, 17 wt%, 17.5 wt%, 18 wt%, 18.5 wt%, 19 wt%, 19.5 wt%, 20 wt%, 21 wt%, 22 wt%, 23 wt%, 24 wt%, 25 wt%, 26 wt%, 27 wt%, 28 wt%, 29 wt% or 30 wt%. In addition, the amount of the keratin affinity inhibitor may be in a range of one or more of the above values ​​and one or less of the above values.

[0084] For example, the content range of the keratin affinity inhibitor can be set to a range of 0.1 wt% to 18 wt%, 0.5 wt% to 17 wt%, 1 wt% to 16 wt%, 2 wt% to 15 wt%, 3 wt% to 14 wt%, 4 wt% to 13 wt%, 5 wt% to 20 wt%, 8 wt% to 20 wt%, 10 wt% to 16 wt%, 1 wt% to 10 wt%, 5 wt% to 15 wt%, 0.1 wt% to 20 wt%, 10 wt% to 15 wt%, 10 wt% to 30 wt%, 20 wt% to 30 wt% or 0.01 wt% to 30 wt%.

[0085] And, the content of the keratin affinity inhibitor may be applied as one or more of the above values, or may be applied as one or less of the above values. For example, the content of the keratin affinity inhibitor may be applied as 0.01 wt% or more, 0.05 wt% or more, 0.1 wt% or more, 0.5 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, 5 wt% or more, 6 wt% or more, 7 wt% or more, 8 wt% or more, 9 wt% or more, 10 wt% or more, or 15 wt% or less, 30 wt% or less, 25 wt% or less, 20 wt% or less, 19 wt% or less, 18 wt% or less, 17 wt% or less, 16 wt% or less, 15 wt% or less, 14 wt% or less, 13 wt% or less, 12 wt% or less, 11 wt% or less, or 10 wt% or less.

[0086] In one embodiment, the keratin affinity inhibitor may comprise cystamine dihydrochloride. In another embodiment, the keratin affinity inhibitor may further comprise at least one selected from lauryl choline, tricaprylin, and octenidine dihydrochloride. Depending on the implementation, the keratin affinity inhibitor may be used alone or in combination of two or more of the aforementioned keratin affinity inhibitor components.

[0087] Meanwhile, a pharmaceutical composition for the prevention or treatment of tinea according to one embodiment may further include a chelating agent. In one embodiment, the content of the chelating agent may be 0.0001 to 5 wt% based on the total weight of the composition.

[0088] For example, the content of the chelating agent may be 0.0001 wt%, 0.001 wt%, 0.01 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt% or 5 wt%. In addition, the content of the chelating agent may be in a range of one or more of the above values ​​and one or less of the above values.

[0089] For example, the content range of the chelating agent can be set to be 0.0001 wt% to 5 wt%, 0.0001 wt% to 4 wt%, 0.0001 wt% to 3 wt%, 0.0001 wt% to 2 wt%, 0.0001 wt% to 1 wt%, 0.0001 wt% to 0.5 wt%, 0.01 wt% to 5 wt%, 0.01 wt% to 1 wt%, 0.01 wt% to 0.1 wt%, or 0.1 wt% to 5 wt%.

[0090] In addition, the content of the chelating agent may be applied as one or more of the above values, or may be applied as one or less of the above values. For example, the content of the chelating agent may be applied as 0.0001 wt% or more, 0.001 wt% or more, 0.01 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, or 4.5 wt% or more, or 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, 0.5 wt% or less, 0.1 wt% or less, 0.01 wt% or less, 0.001 wt% or less, 0.005 wt% or less, or 0.007 wt% or less.

[0091] In one embodiment, the chelating agent may comprise trisodium ethylenediamine disuccinate.

[0092] In one embodiment, a pharmaceutical composition for the prevention or treatment of tinea versicolor may further comprise an additive. In one embodiment, the additive may comprise at least one selected from a vehicle, an antioxidant, and a pH adjuster.

[0093] In one embodiment, the vehicle is an additive capable of maintaining the shape of the composition. According to one embodiment, the vehicle may be applied as at least one selected from the group consisting of purified water, glycerin, mineral oil, lanolin oil, sorbitol, ethanol, isopropyl alcohol, acetone, ethyl acetate, and mixtures thereof. Preferably, purified water, ethanol, isopropyl alcohol, glycerin, or the like may be used as the vehicle. In one embodiment, the content of the vehicle may be set in the range of 0.1 to 90 wt% based on the total weight of the composition.

[0094] As a specific example, the content of the vehicle is 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt%, 8 wt%, 8.5 wt%, 9 wt%, 9.5 wt%, 10 wt%, 10.5 wt%, 11 wt%, 11.5 wt%, 12 wt%, 12.5 wt%, 13 wt%, 13.5 wt%, 14 wt%, It can be prepared as 14.5 wt%, 15 wt%, 15.5 wt%, 16 wt%, 16.5 wt%, 17 wt%, 17.5 wt%, 18 wt%, 18.5 wt%, 19 wt%, 19.5 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 65 wt%, 70 wt%, 75 wt%, 80 wt%, 85 wt% or 90 wt%.

[0095] In one embodiment, the antioxidant may be at least one selected from the group consisting of butylhydroxytoluene, butylhydroxyanisole, ferulic acid, ascorbic acid, and tocopherol. Preferably, butylhydroxytoluene may be used as the antioxidant. In one embodiment, the content of the antioxidant may be set in the range of 0.0001 to 1 wt% based on the total weight of the composition.

[0096] For example, the content of the antioxidant may be 0.0001 wt%, 0.001 wt%, 0.01 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt% or 1 wt%.

[0097] In one embodiment, the pH adjuster may be applied as at least one selected from the group consisting of citric acid, pentetic acid, tartaric acid, and succinic acid, and preferably citric acid may be used as the pH adjuster. In one embodiment, the content of the pH adjuster may be set in the range of 0.0001 to 5 wt% based on the total weight of the composition.

[0098] As a specific example, the content of the pH adjuster can be set to 0.0001 wt%, 0.001 wt%, 0.01 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 2 wt%, 3 wt%, 4 wt% or 5 wt%.

[0099] In one embodiment, a pharmaceutical composition for the prevention or treatment of tinea versicolor may be formulated in at least one dosage form selected from the group consisting of a liquid, an aerosol, a stick, and a semi-solid formulation. In one embodiment, the semi-solid formulation may include at least one of a gel, a lotion, a cream, and an ointment.

[0100] The pH of the pharmaceutical composition for preventing or treating tinea according to one embodiment may be applied as 2 to 10. As a specific example, the pH of the pharmaceutical composition for preventing or treating tinea may be prepared as 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In addition, the pH of the pharmaceutical composition for preventing or treating tinea according to one embodiment may be in a range of one or more of the above values ​​and one or less of the above values. For example, the pH range of the pharmaceutical composition may be prepared in a range of 2 to 10, 4 to 10, 5 to 9.5, 6 to 8, or 7 to 8.

[0101] And, according to one embodiment, the density of the pharmaceutical composition for preventing or treating tinea may be applied as 0.5 to 2 g / cm3. As a specific example, the density of the pharmaceutical composition for preventing or treating tinea may be applied as 0.5 g / cm3, 0.6 g / cm3, 0.7 g / cm3, 0.8 g / cm3, 0.9 g / cm3, 1 g / cm3, 1.1 g / cm3, 1.2 g / cm3, 1.3 g / cm3, 1.4 g / cm3, 1.5 g / cm3, 1.6 g / cm3, 1.7 g / cm3, 1.8 g / cm3, 1.9 g / cm3 or 2 g / cm3.

[0102] Additionally, in one embodiment, the density of the pharmaceutical composition of the external preparation containing the antifungal agent as an active ingredient may be in a range of one or more of the above values ​​and one or less of the above values. For example, the density range of the pharmaceutical composition may be set to be in a range of 0.5 to 2 g / cm3, 0.8 to 2 g / cm3, 1.2 to 1.8 g / cm3, 1.5 to 1.7 g / cm3, or 1.5 to 2 g / cm3.

[0103] In one embodiment, the moisture content of the pharmaceutical composition for preventing or treating vitiligo is measured by the Karl Fischer method, and the moisture content of the composition measured by the Karl Fischer method may be 0.1 to 90 wt%. As a specific example, the moisture content of the pharmaceutical composition for the prevention or treatment of tinea is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, It can be applied at 86%, 87%, 88%, 89% or 90%.

[0104] In addition, the moisture content of the pharmaceutical composition of the external preparation containing the antifungal agent as an active ingredient may be in a range of one or more of the above values ​​and one or less of the above values. For example, the moisture content of the pharmaceutical composition may be in a range of 0.1 to 90%, 0.5 to 80%, 1 to 70%, 2 to 5%, 3 to 5%, 5 to 85%, 7 to 60%, 8 to 55%, 9 to 50%, 10 to 45%, 10 to 20%, 10 to 15%, 10 to 13%, 15 to 40%, or 20 to 35%.

[0105] In one embodiment, the surface tension of the pharmaceutical composition for preventing or treating vitiligo may be 1 to 76 dyn / cm. As a specific example, the surface tension of the pharmaceutical composition for the prevention or treatment of tinea is 1 dyn / cm, 2 dyn / cm, 3 dyn / cm, 4 dyn / cm, 5 dyn / cm, 6 dyn / cm, 7 dyn / cm, 8 dyn / cm, 9 dyn / cm, 10 dyn / cm, 11 dyn / cm, 12 dyn / cm, 13 dyn / cm, 14 dyn / cm, 15 dyn / cm, 16 dyn / cm, 17 dyn / cm, 18 dyn / cm, 19 dyn / cm, 20 dyn / cm, 21 dyn / cm, 22 dyn / cm, 23 dyn / cm, 24 dyn / cm, 25 dyn / cm, 26 dyn / cm, 27 dyn / cm, 28 dyn / cm, at 25°C. 29dyn / cm, 30dyn / cm, 31dyn / cm, 32dyn / cm, 33dyn / cm, 34dyn / cm, 35dyn / cm, 36dyn / cm, 37dyn / cm, 38dyn / cm, 39dyn / cm, 40dyn / cm, 41dyn / cm, 42dyn / cm, 43dyn / cm, 44dyn / cm, 45dyn / cm, 46dyn / cm, 47dyn / cm, 48dyn / cm, 49dyn / cm, 50dyn / cm, 51dyn / cm, 52dyn / cm, 53dyn / cm, 54dyn / cm, 55dyn / cm, 56dyn / cm, 57dyn / cm, 58dyn / cm, It can be applied as 59dyn / cm, 60dyn / cm, 61dyn / cm, 62dyn / cm, 63dyn / cm, 64dyn / cm, 65dyn / cm, 66dyn / cm, 67dyn / cm, 68dyn / cm, 69dyn / cm, 70dyn / cm, 71dyn / cm, 72dyn / cm, 73dyn / cm, 74dyn / cm, 75dyn / cm or 76dyn / cm.

[0106] Additionally, the surface tension of the pharmaceutical composition of the external preparation containing an antifungal agent as an active ingredient may be in a range of one or more of the above values ​​and one or less of the above values. For example, the surface tension range of the pharmaceutical composition may be 1 dyn / cm to 76 dyn / cm, 5 dyn / cm to 60 dyn / cm, 10 dyn / cm to 50 dyn / cm, 15 dyn / cm to 65 dyn / cm, 20 dyn / cm to 60 dyn / cm, 10 dyn / cm to 40 dyn / cm, 15 dyn / cm to 30 dyn / cm, 25 dyn / cm to 55 dyn / cm, 30 dyn / cm to 50 dyn / cm, 41 dyn / cm to 50 dyn / cm, 42 dyn / cm to 50 dyn / cm, 43 dyn / cm to 50 dyn / cm, 44 dyn / cm to 50 dyn / cm, 45 dyn / cm to 50 dyn / cm, 41 dyn / cm to It can be provided in the range of 45 dyn / cm, 41 dyn / cm to 44 dyn / cm, 41 dyn / cm to 43 dyn / cm or 50 dyn / cm to 76 dyn / cm.

[0107] In one embodiment, the daily dosage of the pharmaceutical composition for the prevention or treatment of tinea versicolor may be 0.01 to 60 g / day. For example, when the pharmaceutical composition is applied as an external agent, the daily application amount is 0.01g / day, 0.02g / day, 0.03g / day, 0.04g / day, 0.05g / day, 0.06g / day, 0.07g / day, 0.08g / day, 0.09g / day, 0.1g / day, 0.2g / day, 0.3g / day, 0.4g / day, 0.5g / day, 0.6g / day, 0.7g / day, 0.8g / day, 0.9g / day, 1g / day, 2g / day, 3g / day, 4g / day, 5g / day, 6g / day, 7g / day, 8g / day, 9g / day, 10g / day, 11g / day, 12g / day, 13g / day, 14g / day, 15g / day, 16g / day, 17g / day, 18g / day, 19g / day, 20g / day, 21g / day, 22g / day, 23g / day, 24g / day, 25g / day, 26g / day, 27g / day, 28g / day, 29g / day, 30g / day, 31g / day, 32g / day, 33g / day, 34g / day, 35g / day, 36g / day, 37g / day, 38g / day, 39g / day, 40g / day, 41g / day, 42g / day, 43g / day, 44g / day, 45g / day, 46g / day, It can be applied as 47g / day, 48g / day, 49g / day, 50g / day, 51g / day, 52g / day, 53g / day, 54g / day, 55g / day, 56g / day, 57g / day, 58g / day, 59g / day or 60g / day.

[0108] In addition, when a pharmaceutical composition for topical application containing an antifungal agent as an active ingredient is topically applied, the daily application amount may be in a range of one or more of the above values ​​and one or less of the above values. For example, when a pharmaceutical composition is topically applied, the daily application amount may be in a range of 0.01 to 60 g / day, 0.1 to 60 g / day, 0.01 to 1 g / day, 0.01 to 0.5 g / day, 0.05 to 0.1 g / day, 1 to 60 g / day, 5 to 50 g / day, 10 to 40 g / day, 15 to 35 g / day, or 20 to 30 g / day.

[0109] And, in one embodiment, when the pharmaceutical composition is prepared as an external preparation and applied topically, a method of applying, spraying, or attaching an appropriate amount of the composition to the treatment area of ​​the patient (e.g., nail, skin, etc.) can be used.

[0110] Meanwhile, according to one embodiment, a pharmaceutical composition for preventing or treating tinea may not include cyclomethicone, methylpyrrolidone, and ethylenediamine tetraacetic acid salt. That is, according to one embodiment, since the pharmaceutical composition for preventing or treating tinea does not contain cyclomethicone, methylpyrrolidone, and ethylenediamine tetraacetic acid salt, the harmfulness problem caused by these ingredients can be fundamentally resolved.

[0111] In one embodiment, the pharmaceutical composition for topical application containing an antifungal agent as an active ingredient may be colorless or pale yellow. Furthermore, the pharmaceutical composition according to one embodiment does not crystallize even after being stored at -10°C for at least 2 weeks, and does not crystallize even after being applied to the skin or nail and being stored at room temperature (25°C) for 24 hours.

[0112] The present invention is described in more detail below through specific manufacturing examples. The following manufacturing examples are merely examples intended to aid understanding of the present invention and are not intended to limit or restrict the scope of the present invention.

[0113] Control Examples 1 to 3, Comparative Examples 1 to 3, Control Examples 1 to 15: Preparation of external preparation solution

[0114] A topical solution containing an antifungal agent (luliconazole, efinaconazole, tavaborol) as an active ingredient was prepared according to the procedure below, and the ingredients and composition of each topical solution are as described in Tables 1, 2, and 3 below.

[0115] 1. Preparation of solution A: After dissolving antifungal agents (luliconazole, efinaconazole, tavaborol) in ethanol, 1,2-pentanediol, acetyltributyl citrate, cystamine dihydrochloride, butylhydroxytoluene, and glycerin were sequentially added and dissolved at room temperature (25°C) to prepare solution A.

[0116] 2. Preparation of Solution B: Solution B was prepared by sequentially adding citric acid and trisodium ethylenediamine disuccinate to purified water and dissolving them.

[0117] 3. Solution B was added to solution A, mixed and dissolved, and then filtered through a 0.45 μm filter to produce a transparent external preparation solution.

[0118] 4. The pH of the manufactured external preparation solution was measured and found to be within the range of 4.5 to 7.5, and the surface tension of the manufactured external preparation solution was measured and found to be within the range of 25 to 50 dyn / cm at 25°C.

[0119]

[0120]

[0121]

[0122] Test Example 1. Evaluation of the ability to suppress crystal precipitation at low temperatures

[0123] Each sample of Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 1 to 15 was added to a 20 ml vial at 10 ml each, stored in a low-temperature freezer at -10°C for 2 weeks, and the crystal and precipitate formation state was observed with the naked eye at room temperature (25°C). The results are shown in Table 4.

[0124]

[0125] Referring to the results in Table 4, in the case of Comparative Examples 1, 2, and 3 and Manufacturing Examples 3, 8, and 13, in which the weight ratio of 1,2-pentanediol and acetyltributyl citrate as crystal growth inhibitors was 1:2 and the content of the crystal growth inhibitor was 30 wt% based on the total weight of the external preparation solution, it was confirmed that no crystal precipitation phenomenon occurred at all even after storage at -10°C for 2 weeks.

[0126] Test Example 2. Evaluation of the ability to suppress crystal precipitation during drying after application of an external preparation

[0127] Each sample of Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 1 to 15 was dropped in an amount of 0.5 ml onto a slide glass measuring 26 mm in width × 76 mm in height, applied with a cotton swab, and observed with the naked eye after 24 hours at room temperature (25°C). The results are shown in Table 5.

[0128]

[0129] Referring to the results in Table 5, in the case of Comparative Examples 1, 2, and 3 and Manufacturing Examples 3, 8, and 13, in which the weight ratio of 1,2-pentanediol and acetyltributyl citrate as crystal growth inhibitors was 1:2 and the content of the crystal growth inhibitor was 30 wt% based on the total weight of the external preparation solution, it was confirmed that no crystal precipitation phenomenon occurred at all even after 24 hours at room temperature after applying the external preparation to a slide glass.

[0130] Test Example 3. Susceptibility Test for Antibacterial Activity Evaluation

[0131] Typically, clinical treatment outcomes can be predicted through antifungal drug susceptibility testing. The test strains for susceptibility testing to evaluate antimicrobial activity are representative pathogens that cause superficial fungal infections, such as Trichophyton rubrum, Trichophyton mentagrophytes, and Candida albicans. To evaluate antimicrobial activity against the three microorganisms mentioned above, this experiment was conducted using the tube dilution technique. Antimicrobial activity was evaluated by determining the minimum growth inhibitory concentration (MIC) for each microorganism. 90 ; The results of comparing Control Examples 1, 2, 3 and Comparative Examples 1, 2, 3 and Manufacturing Examples 3, 8, 13 as Minimum Inhibition Concentration (MIC) are as shown in Table 6 below. The minimum growth inhibition concentration test was performed according to the classification of the CLSI (Clinical and Laboratory Standards Institute) standards, and for Trichophyton levrum and Trichophyton mentagrophytes as fungi, the test was performed using the CLSI M38-A2:2008 test method, and for Candida albicans as yeast, the test was performed using the CLSI M27-A3:2008 test method.

[0132] 1) Pre-culture of test bacteria

[0133] ①Trichophyton rubrum, Trichophyton mentagrophytes: Spread on OA (OA; Oatmeal 6%, Agar 1.25%, pH 6.0) medium and cultured at 30±2℃ for 4 to 5 days.

[0134] ②Candida albicans: Inoculated onto Sabouraud Dextrose Agar (SDA) medium and cultured at 35±2℃ for 20 to 24 hours.

[0135] 2) Preparation of test bacterial solution and spore suspension

[0136] ① Trichophyton rubrum, Trichophyton mentagrophytes: After buffering 0.165 mol / L of 3-N-morpholinolinopropane sulfonic acid (MOPS) in RPMI 1640 medium (Gibco), a spore suspension of (2∼3)×10³CFU / ml was prepared and used as a test bacterial solution.

[0137] ② Candida albicans: 5.0 × 10 in RPMI 1640 medium (Gibco) buffered with 0.165 mol / L 3-ene-morpholinopropane sulfonic acid 2 ∼2.5×10 3 A spore suspension of CFU / ml was prepared and used as a test bacterial solution.

[0138] 3) Inoculation of test bacteria solution

[0139] ① Trichophyton rubrum, Trichophyton mentagrophytes: 1 ml of the test bacteria solution was inoculated into each well containing the test solution at each concentration. A well containing 0.2 ml of the solution (Control Examples 1, 2, 3, Comparative Examples 1, 2, 3, Preparation Examples 3, 8, 13) in RPM1640 (buffered with MOPS 0.165 mol / L) medium was used as a negative control group, and a well containing 0.1 ml of the solution (Control Examples 1, 2, 3, Comparative Examples 1, 2, 3, Preparation Examples 3, 8, 13) and 0.1 ml of the test bacteria solution in RPM1640 (buffered with MOPS 0.165 mol / L) medium was used as a positive control group. The tubes that had been treated with the test bacteria solution were cultured at 35±2℃ for 46 to 50 hours.

[0140] ② Candida albicans: 0.9 ml of the test bacteria solution was inoculated into each well containing the test solution at each concentration. The well containing 1.0 ml of the solution (Control Examples 1, 2, 3, Comparative Examples 1, 2, 3, Preparation Examples 3, 8, 13) in RPM1640 (buffered with MOPS 0.165 mol / L) medium was used as a negative control group, and the well containing 0.1 ml of the solution (Control Examples 1, 2, 3, Comparative Examples 1, 2, 3, Preparation Examples 3, 8, 13) and 0.9 ml of the test bacteria solution in RPM1640 (buffered with MOPS 0.165 mol / L) medium was used as a positive control group. The tubes that had been treated with the test bacteria solution were cultured at 35±2℃ for 24 to 48 hours.

[0141] 4) Judging the results

[0142] When the growth of bacteria was visually observed in each tube after incubation, the minimum concentration at which bacteria did not grow was defined as the minimum growth inhibitory concentration (MIC). 90 ) was used. After culture, no growth should be observed in the negative control group, and growth of bacteria should be observed in the positive control group. The results obtained using the above antibacterial test method are shown in Table 6.

[0143]

[0144] As can be seen from the results in Table 6, for Trichophyton leuvenum, Preparation Examples 3, 8, and 13 were 2.6 to 3.2 times better than Control Examples 1, 2, and 3, and 1.6 to 2.3 times better than Comparative Examples 1, 2, and 3, respectively; for Trichophyton mentagrophytes, Preparation Examples 3, 8, and 13 were 2.1 to 4.4 times better than Control Examples 1, 2, and 3, and 1.7 to 2.3 times better than Comparative Examples 1, 2, and 3, respectively; and for Candida albicans, Preparation Examples 3, 8, and 13 were 2.1 to 2.5 times better than Control Examples 1, 2, and 3, and 1.8 to 2.3 times better than Comparative Examples 1, 2, and 3, respectively. Therefore, since the pharmaceutical composition according to the manufacturing examples shows good susceptibility test results against the causative agent causing tinea, it can be predicted that it will not only be able to treat the aforementioned causative agent simultaneously, but will also show excellent clinical treatment results.

[0145] <Antifungal agent content analysis method>

[0146] In the following test examples 4, 5, and 6, content analysis of luriconazole was performed using a UV-Visible spectrophotometer under the conditions below.

[0147] * Analysis of the content of luliconazole

[0148] - Device: Mega-800 (Scinco, Korea), double beam method

[0149] -Measuring cell: 10mm quartz cuvettes

[0150] -Solvent: Methanol

[0151] -Preparation of standard solution: Dissolve 50 mg of luriconazole standard in 30 ml of methanol, sonicate for 10 minutes, fill to 50 ml with methanol, and dilute 1 ml of this solution with 100 ml of methanol.

[0152] - Preparation of sample treatment solution: Accurately weigh about 1 gram of the solution to be used as a sample, dissolve in 70 ml of methanol, sonicate for 10 minutes, fill to 100 ml with methanol, filter with Whatman filter paper, and dilute 5 ml of the filtered solution with 50 ml of methanol.

[0153] -Measurement procedure: Measure the absorbance of the standard solution and sample treatment solution using the blank cell as a control at 296 nm on an ultraviolet-visible spectrophotometer.

[0154]

[0155] In the following test examples 4, 5, and 6, the content analysis of efinaconazole was performed using high-performance liquid chromatography (HPLC) under the conditions below.

[0156] * Content analysis of efinaconazole

[0157] - Device: Agilent 1100 (DAD); Concentration gradient over time

[0158] -Column: Inertsil ODS3V (250×4.6mm, 5.0μm)

[0159] -Column temperature: 40℃

[0160] -Mobile phase: ⓐBuffer solution ⓑAcetonitrile:methanol (50:50 volume%)

[0161] -Flow rate: 1.0ml / min

[0162] -Detector: UV detector

[0163] - Detection wavelength: 210 nm

[0164] -Sample injection volume: 10.0μl

[0165] -Sample concentration: 0.3mg / ml

[0166] *ⓐ Preparation of buffer solution: Dissolve 1.36 g of KH2PO4 and 2.16 g of 1-Octanesulfonic acid sodium in 1,000 ml of purified water, adjust the pH to 2.5, and filter and degas through a 0.45 μ membrane filter.

[0167]

[0168] In the following test examples 4, 5, and 6, the content analysis of tababolol was performed using a UV-Visible spectrometer under the conditions below.

[0169] * Content analysis of tababolol (weight%)

[0170] - Device: Mega-800 (Scinco, Korea), double beam method

[0171] -Measuring cell: 10mm quartz cuvettes

[0172] -Solvent: Methanol

[0173] -Preparation of standard solution: Dissolve 50 mg of tababorole standard in 30 ml of methanol, sonicate for 10 minutes, fill to 50 ml with methanol, and then dilute 1 ml of this solution with 100 ml of methanol.

[0174] - Preparation of sample treatment solution: Accurately weigh about 1 gram of the solution to be used as a sample, dissolve in 70 ml of methanol, sonicate for 10 minutes, fill to 100 ml with methanol, filter with Whatman filter paper, and dilute 5 ml of the filtered solution with 50 ml of methanol.

[0175] -Measurement procedure: Measure the absorbance of the standard solution and sample treatment solution using the blank cell as a control at 272 nm on an ultraviolet-visible spectrophotometer.

[0176]

[0177] Test Example 4. Evaluation of Keratin Affinity Inhibition Performance

[0178] After freezing the cow hoof with liquid nitrogen, it was ground into a powder with a particle size of 5 mm or less, sterilized with ethylene oxide gas, and then washed and degreased sequentially with saline solution, distilled water, ethanol / ether (1 / 1, v / v%), and acetone, and dried to make keratin powder. In a 30 ml glass vial, the keratin powder and the solutions of Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 3, 8, and 13 were mixed at a certain ratio (0.5 ml of solution per 1 g of keratin powder), shaken in a 37°C water bath for 2 hours, centrifuged at 1,500 rpm for 5 minutes, and the resulting supernatant was taken to analyze the concentration of the unadsorbed drug on keratin, and the adsorption rate and the keratin affinity inhibition rate for the Control Example were obtained as follows, and the results are shown in Table 7.

[0179] **Keratin adsorption rate (%) = {(added drug concentration - drug concentration in supernatant) / added drug concentration} × 100

[0180]

[0181] As described in Table 7, the keratin affinity reduction rate (%) was 3.4% for Comparative Example 1 and 13.6% for Manufacturing Example 3 compared to Control Example 1, 3.8% for Comparative Example 2 and 14.3% for Manufacturing Example 8 compared to Control Example 2, and 3.4% for Comparative Example 3 and 15.8% for Manufacturing Example 13 compared to Control Example 3. That is, it can be seen that cystamine dihydrochloride included in the composition shows a very good effect as a keratin affinity inhibitor and thus plays an important role in enhancing drug permeability.

[0182] Test Example 5. Skin Permeability Evaluation Using Human Skin

[0183] Human skin was used, and the skin permeation of antifungal agents was evaluated using solutions according to Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 1 to 15 in a Franz Diffusion Cell. Human skin was HuSKin (Hans Biomed Co.,) and after hydration for 2 hours, the hydrated skin was mounted on the Franz diffusion cell, and 200 μl of each test sample was applied to the donor compartment, and 5 ml of phosphate-buffered saline (PBS) containing 1.0% (w / v) Tween 80 and 0.002% (w / v) kanamycin sulfate was filled into the acceptor compartment, and the diffusion area was 1.13㎠. The sample collection amount was 200 μl for each measurement, and the same amount of solution in the acceptor compartment was replenished. The stirring speed was 600 rpm, the temperature was 37±0.5℃, and the number of repetitions per test was three. Sampling was performed every 24 and 48 hours. Each sample collected was analyzed according to the antifungal agent content analysis method described above, and the results are presented in Tables 8, 9, and 10.

[0184]

[0185] As described in Table 8, Manufacturing Example 3 showed the highest permeation concentration of 2.5 times and 1.3 times for 24 hours and 3.3 times and 1.6 times for 48 hours compared to Control Example 1 and Comparative Example 1. Therefore, when the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate weight ratio is 1:2) is contained in an amount of 30 wt% based on the total weight of the composition and the keratin affinity inhibitor (cystamine dihydrochloride) is contained in an amount of 10 wt% based on the total weight of the composition, the treatment efficiency of tinea pedis can be further improved.

[0186]

[0187] As described in Table 9, Manufacturing Example 8 showed the highest permeation concentration of 2.6 times and 1.5 times for 24 hours and 3.8 times and 1.6 times for 48 hours compared to Control Example 2 and Comparative Example 2. Therefore, when the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate weight ratio is 1:2) is contained in an amount of 30 wt% based on the total weight of the composition and the keratin affinity inhibitor (cystamine dihydrochloride) is contained in an amount of 10 wt% based on the total weight of the composition, the treatment efficiency of tinea pedis can be further improved.

[0188]

[0189] As described in Table 10, Manufacturing Example 13 showed the highest permeation concentration of 3.2 times and 1.5 times for 24 hours and 3.7 times and 1.8 times for 48 hours, compared to Control Example 3 and Comparative Example 3. Therefore, when the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate weight ratio is 1:2) is contained in an amount of 30 wt% based on the total weight of the composition and the keratin affinity inhibitor (cystamine dihydrochloride) is contained in an amount of 10 wt% based on the total weight of the composition, the treatment efficiency of tinea pedis can be further improved.

[0190] Test Example 6. Evaluation of human nail penetration

[0191] A fingernail cut from a healthy adult was obtained, washed with saline solution, and hydrated in saline solution for 2 hours. After mounting the hydrated fingernail on a Franz diffusion cell, 100 μl of each sample (Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 1 to 15) was applied once a day for 10 days to the donor compartment, and 200 μl of a sample was collected from the acceptor compartment. The acceptor compartment was filled with 5 ml of phosphate-buffered saline solution containing 1.0% (w / v) Tween 80 and 0.002% (w / v) kanamycin sulfate, and the diffusion area was 1.13 cm2. The sample collection amount was 200 μl for each measurement, and the same amount of solution in the acceptor compartment was replenished. The stirring speed was 600 rpm, the temperature was 32±0.5℃, and the number of repetitions per test was 3. Sampling was performed at 1, 3, 7, 13, 21, and 24 hours on the first day, and every 48 hours from the second to the tenth day. Each collected sample was analyzed according to the content analysis method of the antifungal agent described above, and the obtained results were confirmed as the average value of the cumulative penetration concentration (ug / ml) and standard deviation. The results are as shown in Figures 1, 2, and 3.

[0192] Figure 1 is a graph showing the cumulative permeation concentration results of luriconazole for 10 days according to Control Example 1, Comparative Example 1, and Manufacturing Examples 1 to 5. Referring to Figure 1, Manufacturing Example 3 showed the highest permeation concentration compared to Control Example 1 and Comparative Example 1, with permeation concentrations of 6.5 times and 1.4 times on the first day, 5.3 times and 1.4 times on the second day, 4.7 times and 1.7 times on the sixth day, and 3.9 times and 1.8 times on the final day, the 10th day. Therefore, it can be seen that Preparation Example 3, which contains 30 wt% of the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate in a weight ratio of 1:2) based on the total weight of the composition and 10 wt% of the keratin affinity inhibitor (cystamine dihydrochloride) based on the total weight of the composition, can treat tinea pedis and tinea skini more effectively than Control Example 1, which does not contain a crystal growth inhibitor and a keratin affinity inhibitor, and Comparative Example 1, which does not contain a keratin affinity inhibitor.

[0193] Figure 2 is a graph showing the cumulative permeation concentration results of efinaconazole for 10 days according to Control Example 2, Comparative Example 2, and Manufacturing Examples 6 to 10. Referring to Figure 2, Manufacturing Example 8 showed the highest permeation concentration compared to Control Example 2 and Comparative Example 2, with permeation concentrations of 6.1 times and 1.3 times on the first day, 4 times and 1.2 times on the second day, 3.5 times and 1.3 times on the sixth day, and 4.5 times and 1.5 times on the final day, the 10th day. Therefore, it can be seen that Preparation Example 8, which contains 30 wt% of the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate in a weight ratio of 1:2) based on the total weight of the composition and 10 wt% of the keratin affinity inhibitor (cystamine dihydrochloride) based on the total weight of the composition, can treat tinea pedis and tinea skini more effectively than Control Example 2, which does not contain a crystal growth inhibitor and a keratin affinity inhibitor, and Comparative Example 2, which does not contain a keratin affinity inhibitor.

[0194] Figure 3 is a graph showing the results of the cumulative permeation concentration of tababolol for 10 days according to Control Example 3, Comparative Example 3, and Manufacturing Examples 11 to 15. Referring to Figure 3, Manufacturing Example 13 showed the highest permeation concentration compared to Control Example 3 and Comparative Example 3, with permeation concentrations of 6.3 times and 1.2 times on the first day, 5.4 times and 1.2 times on the second day, 4.4 times and 1.5 times on the sixth day, and 5.0 times and 1.7 times on the final day, the 10th day. Therefore, it can be seen that Preparation Example 13, which contains 30 wt% of the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate in a weight ratio of 1:2) based on the total weight of the composition and 10 wt% of the keratin affinity inhibitor (cystamine dihydrochloride) based on the total weight of the composition, can treat tinea pedis and tinea cutis more effectively than Control Example 3, which does not contain a crystal growth inhibitor and a keratin affinity inhibitor, and Comparative Example 3, which does not contain a keratin affinity inhibitor.

[0195] Test Example 7. Storage Stability Evaluation

[0196] Control Examples 1 to 3, Comparative Examples 1 to 3, and Manufacturing Examples 3, 8, and 13 were each placed in 20 ml transparent vials (10 ml each), hermetically sealed, and stored at 50°C for 4 weeks. The UV-visible absorption spectra of the samples at the beginning and after 4 weeks at 50°C were measured. Measurements were made at 400 nm and 600 nm using a Mega-800 (Scinco, Korea) spectrophotometer, and the evaluation results are shown in Tables 11 and 12 below.

[0197]

[0198]

[0199] As described in Tables 11 and 12, Preparation Examples 3, 8, and 13 obtained very stable results compared to Control Examples 1, 2, and 3 and Comparative Examples 1, 2, and 3. In the absorbance at 400 nm, Preparation Examples 3, 8, and 13 showed an increase in absorbance of 1.4 to 1.8%, whereas Control Examples 1, 2, and 3 showed an increase of 11.3 to 13.6%, and Comparative Examples 1, 2, and 3 showed an increase of 4.0 to 6.7%. In the absorbance at 600 nm, Preparation Examples 3, 8, and 13 showed an increase in absorbance of 1.4 to 2.3%, whereas Control Examples 1, 2, and 3 showed an increase of 11.1 to 14.6%, and Comparative Examples 1, 2, and 3 showed an increase of 5.3 to 7.1%. Looking at the stability results, Control Examples 1, 2, and 3, which did not contain a crystal growth inhibitor and a keratin affinity inhibitor, had the worst stability, and Comparative Examples 1, 2, and 3, which only contained a crystal growth inhibitor, also had poor stability. In comparison, Preparation Examples 3, 8, and 13, which contained 30 wt% of the crystal growth inhibitor (1,2-pentanediol: acetyltributyl citrate in a weight ratio of 1:2) based on the total weight of the composition, and 10 wt% of the keratin affinity inhibitor (cystamine dihydrochloride) based on the total weight of the composition, had the best stability.

[0200] As described above, according to various embodiments of the present invention, by inhibiting crystal growth of the poorly soluble antibacterial agents luliconazole, efinaconazole, and tavaborole as active ingredients, the solubility of the drug is improved, so that the phenomenon of crystal precipitation does not occur even when the temperature changes during long-term storage, and when the drug is applied to the affected area of ​​the skin or nail, the formation of fine precipitates in the affected area after the volatile solvent evaporates is prevented, thereby significantly improving the permeability of the drug.

[0201] In addition, according to various embodiments of the present invention, there is an advantage in that crystal precipitation is prevented by suppressing crystal growth phenomenon that may occur during the storage period of the drug and after drug application, and affinity with keratin of the skin and nails is suppressed, thereby significantly improving the penetration effect and antibacterial power of the drug.

[0202] In addition, according to various embodiments of the present invention, the stability of the formulation is improved by inhibiting crystal growth of a poorly soluble antibacterial agent, the precipitation of crystals after evaporation of a volatile solvent when applied to the skin and nails is prevented, thereby increasing the antibacterial activity, and the keratin affinity of the antibacterial agent to the nails is inhibited, thereby effectively increasing the drug permeability, thereby maximizing the treatment and prevention effect of tinea.

[0203] In addition, according to various embodiments of the present invention, when applying the drug to the affected area of ​​the skin and nail, the keratin affinity of the antibacterial agent, which is an active ingredient, is suppressed, thereby further increasing the drug permeability, thereby having an excellent effect in preventing and treating tinea.

[0204] In addition, according to various embodiments of the present invention, the effect of preventing crystal precipitation after drug application is excellent, so that medication compliance is high, and the drug permeability and antibacterial power in the skin and nails are very excellent.

[0205] In addition, it does not contain cyclomethicone and N-methylpyrrolidone, which are regulated substances contained in products currently on the market, and ethylenediamine tetraacetic acid salt, which has poor biodegradability, so it is less harmful and more environmentally friendly than products containing these ingredients, and can be widely used as a pharmaceutical composition for external application for the prevention or treatment of tinea.

[0206] In other words, the pharmaceutical composition according to various embodiments of the present invention is composed of an environmentally friendly and non-hazardous composition since it does not use cyclomethicone, an environmentally hazardous substance, ethylenediamineacetic acid salt, an environmentally harmful substance, or methylpyrrolidone, a carcinogenic substance, and has the advantage of excluding harmful ingredients from products currently on the market, improving solubility by inhibiting crystal growth of antifungal agents, and significantly improving drug penetration ability and antibacterial effect of skin and nail plates by reducing keratin affinity.

[0207] In various embodiments of the present invention, cyclomethicone and N-methylpyrrolidone, which are hazardous substances, are not used as excipients, and ethylenediamine tetraacetic acid salt, which has poor biodegradability, is not used as a chelating agent, so there is an advantage of being non-hazardous and very environmentally friendly.

[0208] Finally, according to various embodiments of the present invention, the crystal growth inhibitor as an auxiliary component of the pharmaceutical composition inhibits the crystal growth of the drug, so that precipitation does not occur during long-term storage, and even after applying the drug to the affected area, crystals do not form, thereby improving the permeability of the drug. In addition, the keratin affinity inhibitor as an auxiliary component can further improve the permeability of the drug by significantly reducing the keratin affinity of the drug. That is, the pharmaceutical composition according to various embodiments significantly increases the permeability of the drug by simultaneously performing the two functions of preventing crystal growth and inhibiting keratin affinity, and also tends to show an excellent increase in antibacterial activity. This improvement in drug permeability and increase in antibacterial activity can contribute to maximizing the preventive or therapeutic effect of skin and nail tinea.

[0209] In addition, the pharmaceutical composition according to various embodiments does not use cyclomethicone, an environmentally hazardous substance, ethylenediamineacetic acid salt, an environmentally toxic substance, and methylpyrrolidone, a carcinogenic substance, and is composed of an environmentally friendly and non-toxic composition, so it is excellent in safety and environmental friendliness for the human body.

[0210] As described above, the present invention has been specifically described by way of examples. However, since the above-described examples are merely preferred examples of the present invention, the present invention should not be understood as being limited to the above-described examples, and the scope of the present invention should be understood by the claims described below and their equivalents.

Claims

1. Antifungal agent; crystal growth inhibitors; and characterized by comprising a keratin affinity inhibitor; A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

2. In paragraph 1, The content of the above antifungal agent is 0.1 to 20 wt% based on the total weight of the composition, The antifungal agent is characterized in that it comprises at least one selected from luriconazole, luriconazole salt, efinaconazole, efinaconazole salt, tavaborole and tavaborole salt. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

3. In paragraph 1, The content of the above crystal growth inhibitor is 0.1 to 70 wt% based on the total weight of the composition, The above crystal growth inhibitor comprises 1,2-pentanediol; and ester compounds; The weight ratio of the above 1,2-pentanediol and ester compound is 1:2, The above ester compound is characterized in that it is at least one selected from the group consisting of acetyltributyl citrate, acetyltriethyl citrate, triethyl citrate and diethyl carbonate. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

4. In paragraph 1, The above keratin affinity inhibitor is characterized in that it contains cystamine dihydrochloride. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

5. In paragraph 4, The above keratin affinity inhibitor further comprises at least one selected from lauryl choline, tricaprylin and octenidine dihydrochloride, The content of the keratin affinity inhibitor is characterized in that it is 0.01 to 30 wt% based on the total weight of the composition. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

6. In paragraph 1, The pharmaceutical composition for preventing or treating tinea versicolor and skin dermatitis further comprises a chelating agent; The content of the above chelating agent is 0.0001 to 5 wt% based on the total weight of the composition, The above chelating agent is characterized in that it comprises trisodium ethylenediamine disuccinate. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

7. In paragraph 1, The additive is characterized in that it comprises at least one selected from a vehicle, an antioxidant and a pH adjuster. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

8. In paragraph 1, The pharmaceutical composition for preventing or treating tinea pedis and skin ringworm has at least one formulation selected from a liquid formulation, an aerosol formulation, a stick formulation, and a semi-solid formulation, wherein the semi-solid formulation includes at least one of a gel formulation, a lotion formulation, a cream formulation, and an ointment formulation. The pH of the pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis is 2 to 10, The density of the pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis is characterized by being 0.01 to 2 g / cm3. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

9. In paragraph 1, The pharmaceutical composition for preventing or treating tinea versicolor and skin dermatitis does not contain cyclomethicone, methylpyrrolidone and ethylenediamine tetraacetic acid salt. The pharmaceutical composition for preventing or treating tinea pedis and skin dermatitis is characterized in that the moisture content measured by the Karl Fischer method is 0.1 to 90 wt%, the surface tension of the pharmaceutical composition for preventing or treating tinea pedis and skin dermatitis is 1 to 76 dyn / cm, and the daily application amount of the pharmaceutical composition for preventing or treating tinea pedis and skin dermatitis when applied topically is 0.001 to 60 g / day. A pharmaceutical composition for the prevention or treatment of tinea versicolor and skin dermatitis.

Citation Information

Patent Citations

  • Compositions and methods for treating fungal infection of the nail

    KR1020120038444A

  • Stabilized efinaconazole compositions

    KR1020160068812A

  • Control point instrumentation system

    KR1020230158367A

  • Pharmaceutical composition for preventing or treating tinea

    KR102217617B1

  • Pharmaceutical composition for preventing or treating tinea

    KR102597564B1